BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//APO - ECPv6.14.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:APO
X-ORIGINAL-URL:https://www.apo-tokyo.org
X-WR-CALDESC:Events for APO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20260101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261006
DTEND;VALUE=DATE:20261017
DTSTAMP:20261001T033715
CREATED:20260928T052319Z
LAST-MODIFIED:20260928T052319Z
UID:90492-1791244800-1792195199@www.apo-tokyo.org
SUMMARY:TES on Pharmaceutical and Nutraceutical Industry Development by RCCI
DESCRIPTION:Pakistan’s Pharmaceuticals Export Strategy 2023–2027 identifies pharmaceuticals as a priority export sector and calls for stronger compliance with international production standards\, including more GMP-\, FDA- or EMA-approved plants. URAAN Pakistan\, the government’s Five-Year National Economic Transformation Plan (2024–29)\, likewise emphasizes export-led growth through its 5Es framework: (i) Exports\, (ii) E-Pakistan\, (iii) Environment – Food and Water Security\, (iv) Energy and Infrastructure\, and (v) Equity\, Ethics\, and Empowerment. Against this policy backdrop\, this TES project aims to strengthen participating companies’ readiness for applicable US FDA requirements and highly regulated export markets. \nThis TES project supports Pakistani pharmaceutical and nutraceutical companies in meeting FDA compliance requirements for exports to the USA\, providing expert guidance on production processes\, documentation\, quality control\, and regulatory requirements\, and develops a model FDA compliance framework replicable across the sector. It contributes primarily to the Pillar 3 process and workforce improvement agenda. As a secondary contribution\, its policy recommendations are tagged against Pillar 1\, in which the 2026 KR calls for a multistakeholder committee to define baseline sector productivity KPIs. \nThe 10-day face-to-face TES project will combine expert consultation\, capacity building\, and company-level technical assessment. The resource person(s) will review selected companies’ practices and systems\, identify compliance gaps\, recommend corrective and technical interventions\, and support practical improvement actions. \nFindings and lessons will be consolidated into a model FDA compliance framework for sector-wide replication\, while strengthening workforce capability\, export readiness\, regulatory compliance\, competitiveness\, and productivity. \nFor more details\, please click here.
URL:https://www.apo-tokyo.org/event/tes-on-pharmaceutical-and-nutraceutical-industry-development-by-rcci/
LOCATION:Pakistan
CATEGORIES:Projects
ATTACH;FMTTYPE=image/png:https://www.apo-tokyo.org/wp-content/uploads/2022/06/Multicountry.png
END:VEVENT
END:VCALENDAR